Siemens offers PERCIST quantification tool
Siemens Healthcare Molecular Imaging has offered a new quantification tool to support PERCIST (PET response criteria in solid tumors) and promote the utility of PET/CT imaging in assessing the effectiveness of oncology treatments.
The PERCIST trial provides standard uptake value (SUV)-based metrics to define response criteria designed to complement the standard Response Evaluation Criteria in Solid Tumors (RECIST) trial criteria.
The PERCIST quantification tool evaluates and delineates metabolic information from the tumor. The tool uses an algorithm that automatically identifies peak standard uptake value (SUV) within a volume of interest, rather than the common single pixel measure of SUVmax. The PERCIST quantification tool offers a metric that is less susceptible to statistical variation and noise, according to Siemens.
The PERCIST trial provides standard uptake value (SUV)-based metrics to define response criteria designed to complement the standard Response Evaluation Criteria in Solid Tumors (RECIST) trial criteria.
The PERCIST quantification tool evaluates and delineates metabolic information from the tumor. The tool uses an algorithm that automatically identifies peak standard uptake value (SUV) within a volume of interest, rather than the common single pixel measure of SUVmax. The PERCIST quantification tool offers a metric that is less susceptible to statistical variation and noise, according to Siemens.